Initial PrEP product choice: results from the HPTN 084 open-label extension

被引：0

作者：

Delany-Moretlwe, S. ^{[1
]}

Hanscom, B. ^{[2
]}

Angira, F. ^{[3
]}

Dadabhai, S. ^{[4
]}

Gadama, D. ^{[5
]}

Mirembe, B. ^{[6
]}

Bhondai, M.

Innes, S. ^{[8
]}

Kalonji, D. ^{[9
]}

Makhema, J. ^{[10
]}

Mandima, P. ^{[7
]}

Marais, A. ^{[11
]}

Mpendo, J. ^{[12
]}

Mukwekwerere, P. ^{[7
]}

Mgodi, N.

Naidoo, V. ^{[13
]}

Ntege, P. Nahirya ^{[14
]}

Nuwagaba-Biribonwoha, H. ^{[15
]}

Roos, E. ^{[1
]}

Singh, N. ^{[16
]}

Siziba, B. ^{[7
]}

Spooner, E.

Farrior, J. ^{[17
]}

Rose, S. ^{[17
]}

Piwowar-Manning, E. ^{[18
]}

Burton, M. ^{[19
]}

Soto-Torres, L. ^{[20
]}

Rooney, J. ^{[21
]}

Rinehart, A. ^{[22
]}

Cohen, M.

Hosseinipour, M. ^{[23
,24
]}

机构：

[1] Univ Witwatersrand, Wits RHI, Johannesburg, South Africa

[2] Fred Hutchinson Canc Res Inst, Stat Ctr HIV AIDS Res Prevent, Seattle, WA USA

[3] KEMRI, Kisumu, Kenya

[4] Coll Med Blanytre, Blantyre, Malawi

[5] UNC Project Malawi, Lilongwe, Malawi

[6] Johns Hopkins Univ Res Collaborat, Makerere Univ, Kampala, Uganda

[7] Univ Zimbabwe, Clin Trials Res Ctr, Harare, Zimbabwe

[8] Desmond Tutu Hlth Fdn, Cape Town, South Africa

[9] South African Med Res Council, HIV & Other Infect Dis Res Unit, Durban, South Africa

[10] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana

[11] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto, South Africa

[12] UVRI IAVI, Entebbe, Uganda

[13] Univ Stellenbosch, Desmond Tutu TB Ctr, Stellenbosch, South Africa

[14] Baylor Coll Med, Childrens Fdn Uganda, Kampala, Uganda

[15] Columbia Univ, Mailman Sch Publ Hlth, Eswatini Prevent Ctr, Mbabane, South Africa

[16] South African Med Res Council, Durban, South Africa

[17] FHI360, Durham, NC USA

[18] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[19] Fred Hutchinson Canc Res Inst, Seattle, WA USA

[20] NIAID, Rockville, MD USA

[21] Gilead Sci, Foster City, CA USA

[22] ViiV Healthcare, Durham, NC USA

[23] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[24] UNC Project Malawi, Lilongwe, Malawi

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2023年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

OALBX0203

引用

页数：2

共 50 条

[21] Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study
Naismith, Robert
Cascione, Mark
Grimaldi, Luigi Maria
Hauser, Stephen
Kappos, Ludwig
Montalban, Xavier
Wolinsky, Jerry
Chin, Peter
Garren, Hideki
Julian, Laura
Model, Fabian
Honeycutt, David
NEUROLOGY, 2017, 88
[22] PERAMPANEL AS MONOTHERAPY IN OPEN-LABEL EXTENSION STUDIES
Kwan, Patrick
Mintzer, Scott
Laurenza, Antonio
Patten, Anna
Cartwright, Karen
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A23 - A23
[23] Open-Label Extension Studies: Are They Really Research?
Cho, Mildred K.
AMERICAN JOURNAL OF BIOETHICS, 2014, 14 (03) : 1 - 2
[24] Open-Label Extension Studies: Are They Really Research?
Cho, Mildred K.
AMERICAN JOURNAL OF BIOETHICS, 2014, 14 (04) : 60 - 61
[25] Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
Cork, M. J.
Thaci, D.
Eichenfield, L. F.
Arkwright, P. D.
Hultsch, T.
Davis, J. D.
Zhang, Y.
Zhu, X.
Chen, Z.
Li, M.
Ardeleanu, M.
Teper, A.
Akinlade, B.
Gadkari, A.
Eckert, L.
Kamal, M. A.
Ruddy, M.
Graham, N. M. H.
Pirozzi, G.
Stahl, N.
DiCioccio, A. T.
Bansal, A.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : 85 - 96
[26] Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
Barratt, Jonathan
Barbour, Sean
Brenner, Robert
Cooper, Kerry
Wei, Xuelian
Eren, Necmi
Floege, Juergen
Jha, Vivekanand
Kim, Sung Gyun
Maes, Bart
Phoon, Richard K. S.
Singh, Harmeet
Tesar, Vladimir
Lafayette, Richard
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, : 679 - 687
[27] Consolidated results from the open-label extension study of ecallantide for the treatment of acute attacks of hereditary angioedema
Riedl, M.
MacGinnitie, A.
Stolz, L.
ALLERGY, 2011, 66 : 109 - 109
[28] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
Riedl, M.
Cicardi, M.
Hao, J.
Lu, P.
Li, H.
Manning, M.
Bernstein, J.
Busse, P.
Tachdjian, R.
Gower, R.
Wedner, H.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
[29] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
Hartung, Hans-Peter
Steinman, Lawrence
Bar-Or, Amit
Sheffield, James
Cheng, Chun-Yen
Riolo, Jon
Harris, Sarah
Reardon, Jennifer
Thorpe, Andrew
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1016 - 1017
[30] LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES
Tachdjian, R.
Anderson, J.
Busse, P.
Johnston, D.
Kiani, S.
Nurse, C.
Paes, K.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S38 - S38

← 1 2 3 4 5 →